Abstract
RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Keywords: RNAi, processing body, viral vectors, therapeutical design
Current Pharmaceutical Design
Title: The Design of Vectors for RNAi Delivery System
Volume: 14 Issue: 13
Author(s): Qi Zhao Wang, Ying Hui Lv, Yong Diao and Ruian Xu
Affiliation:
Keywords: RNAi, processing body, viral vectors, therapeutical design
Abstract: RNA interference (RNAi) is a process of double-stranded RNA-dependent post-transciptional gene silencing that occurs mainly in the mRNA processing bodies (P-bodies) of cells. It has become the most powerful and widely used gene strategy for genetic analysis and molecular therapeutics, based on the highly specific and efficient silencing of target genes. The key challenge for achieving effective RNAi in vitro and in vivo is its delivery to the desired organs and into the target cells. The RNAi delivery systems can be either non-viral or viral vectors. The main candidate for RNAi as a therapeutical tool is the viral-based vectors, including retroviruses, adenoviruses, adeno-associated viruses (AAV), lentiviruses and herpes simplex virus-1 (HSV-1). There is a high potential for clinical use of RNAi in treatment of a wide variety of human diseases, including genetic disorders, infectious diseases and cancer. This paper reviews the designs of inducible, tissue specific, hybrid, oncolytic and high-throughput RNAi vectors based on plasmids or viruses, and discusses their specificity, efficiency and safety.
Export Options
About this article
Cite this article as:
Wang Zhao Qi, Lv Hui Ying, Diao Yong and Xu Ruian, The Design of Vectors for RNAi Delivery System, Current Pharmaceutical Design 2008; 14 (13) . https://dx.doi.org/10.2174/138161208799316357
DOI https://dx.doi.org/10.2174/138161208799316357 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Current Cancer Drug Targets Chloride Channel Expression and Functional Diversity in the Immune Cells of Allergic Diseases
Current Molecular Medicine Heterocyclic Amaryllidaceae Alkaloids: Biosynthesis and Pharmacological Applications
Current Topics in Medicinal Chemistry Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Blind Snipers: Relevant Off Target Effects of Non-chemotherapeutic Agents in Oncology: Review of the Literature
Reviews on Recent Clinical Trials Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Local Gene Delivery for Cancer Therapy
Current Gene Therapy Meet Our Editorial Board Member
Current Cancer Therapy Reviews Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy Polymeric Nanomicelles of Soluplus® as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds
Current Nanomedicine Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Germacrone: A Potent Secondary Metabolite with Therapeutic Potential in Metabolic Diseases, Cancer and Viral Infections
Current Drug Metabolism